Most CTC-evaluable patients in TALAPRO-2 had relatively low CTC burden at baseline, with 81.5% having <5 CTCs/7.5 mL and 65.3 ...

The 2026 ESMO annual meeting featured a rapid oral session and a discussant presentation by Dr. Alison Reid discussing three ...

(UroToday.com) The 2026 European Society of Medical Oncology (ESMO) Annual Congress held the session: Genitourinary tumour, ...

This analysis included 58 patients treated with gemcitabine intravesical system monotherapy in the SunRISe-1 cohort who had ...

The 2026 North Central Section of the AUA annual meeting featured a bladder cancer session and a presentation by Dr. Kaitlin Davis discussing regional disparities in bladder cancer mortality rates.

(UroToday.com) The 2026 North Central Section of the AUA annual meeting featured a prostate cancer session and a presentation ...

The 2026 North Central Section of the AUA annual meeting featured a urothelial carcinoma session and a presentation by Dr.

Docetaxel micellar (DM) is a novel polysorbate-free docetaxel formulation that does not require steroid premedication. The aim of this study was to define the safety, pharmacokinetics (PK) and ...

Adjuvant nivolumab is an important postoperative option for high-risk muscle-invasive urothelial carcinoma, but upper tract urothelial carcinoma (UTUC)-specific real-world evidence remains limited.

Andrea Apolo presents a bone metastasis subanalysis from CheckMate-9ER, encompassing roughly 650 patients with metastatic clear cell renal cell carcinoma, around 25% of whom had bone metastases ...

The advent of prostate-specific membrane antigen (PSMA)-targeted radioligand therapies (PSMA-RLT), particularly those based on Lutetium-177 ([177Lu]Lu-PSMA), has substantially reshaped the therapeutic ...

Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder ...